GNPX

Genprex, Inc.
CAPPED RATING

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Genprex, Inc. (GNPX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C
Factor Score 2.5 / 5.0
Momentum
D-
Factor Score 0.8 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.1
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -53.0%
Price Return 12M -97.4%
Catalyst Signal 0.00
Market Cap $1.9M
TTM Revenue N/A
Price / Sales N/A
ROE -203.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) C+ (2.5) C (2.5) D- (0.8) C+ (2.6) C (2.2)
2026-11-05 C+ (2.5) C+ (2.5) C+ (2.5) D- (0.8) C+ (2.7) C (2.2)
2026-10-29 C+ (2.5) C+ (2.5) C+ (2.6) F (0.5) C+ (2.7) C- (2.1)
2026-10-22 C+ (2.5) C+ (2.5) C+ (2.5) F (0.4) C+ (2.6) C- (2.1)
2026-10-15 C+ (2.5) C+ (2.5) C+ (2.5) F (0.4) C+ (2.6) C- (2.1)
Page 1 of 4